Literature DB >> 4940227

Intestinal antigenicity of ovarian mucinous cystadenomas.

R C Nairn, A C Wallace, E P Guli.   

Abstract

Immunofluorescent tracing by rabbit antiserum with specific reactivity against intestinal mucosa revealed cross-reaction with human ovarian mucinous cystadenoma epithelium and not with epithelium of any of several other human mucous epithelia. The mucinous cystadenoma epithelium apparently contains at least one but not all of the specific intestinal mucosal antigens. The findings support the view that such tumours are histogenetically of intestinal type, as might occur for example by unilateral intestinal development of a teratoma.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4940227      PMCID: PMC2008443          DOI: 10.1038/bjc.1971.34

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  3 in total

1.  Mucinous cystadenomas and mucinous cystadenocarcinomas of the ovary; a clinical and pathological study of 355 cases.

Authors:  M CARIKER; M DOCKERTY
Journal:  Cancer       Date:  1954-03       Impact factor: 6.860

2.  An antiserum to ovarian mucinous cyst fluid with colon cancer specificity.

Authors:  C McNeil; J N Ladle; W M Helmick; E Trentelman; M W Wentz
Journal:  Cancer Res       Date:  1969-08       Impact factor: 12.701

3.  Kidney-specific antigen depletion in human renal carcinomas.

Authors:  R C Nairn; T Ghose; A E Tannenberg
Journal:  Br J Cancer       Date:  1966-12       Impact factor: 7.640

  3 in total
  2 in total

1.  Cross-reactivity of normal gastric tissue components with ovarian tumour-associated antigens.

Authors:  J R Dawson; W H Kutteh
Journal:  Br J Cancer       Date:  1980-09       Impact factor: 7.640

2.  Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA.

Authors:  H Halila; M L Huhtala; C Haglund; S Nordling; U H Stenman
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.